A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Inclusion Criteria:

• Newly diagnosed advanced (FIGO stage III-IV) epithelial ovarian, fallopian tube, orprimary peritoneal cancer.

• Completed cytoreductive surgery, including at least a bilateralsalpingo-oophorectomy and partial omentectomy, either prior to chemotherapy (primarysurgery) or following neoadjuvant chemotherapy (interval debulking)

• Completed first-line platinum-based chemotherapy and surgery with a response, in theopinion of the Investigator

• Sufficient tumor tissue for planned analysis

• ECOG performance status of 0 or 1

• Patients must be 20 years of age to consent in Japan, Taiwan and South Korea; in allother participating countries patients must be 18 years of age to consent

Exclusion Criteria:

• Pure sarcomas or borderline tumors or mucinous tumors

• Active second malignancy

• Known central nervous system brain metastases

• Any prior treatment for ovarian cancer, other than the first-line platinum regimen

• Evidence of interstitial lung disease or active pneumonitis

• Active, known or suspected autoimmune disease

• Condition requiring active systemic treatment with either corticosteroids (>10 mgdaily prednisone equivalent) or other immunosuppressive medications